Stay updated on Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe footer’s site revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedAn NIH announcement about terminology during the agency’s transition appears on the page, and the site revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference0.5%

- Check41 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1, reflecting a website software update rather than a change to the clinical trial record.SummaryDifference0.1%

- Check62 days agoChange DetectedThe study record's revision label was updated from v3.6.6 to v3.7.0. This reflects a new version of the page rather than changes to the study content.SummaryDifference0.1%

- Check76 days agoChange DetectedA new revision entry v3.6.6 was added to the study history, and the previous entry v3.6.5 was removed. This is an update to the record's revision metadata on ClinicalTrials.gov rather than substantive content.SummaryDifference0.1%

- Check97 days agoChange DetectedA new revision entry v3.6.5 was added to the study history as the latest revision. The previous v3.6.4 entry was removed from the current change set.SummaryDifference0.1%

Stay in the know with updates to Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.